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Atherosclerosis is a chronic inflammatory dis-
ease in which lipoproteins accumulate, eliciting 
an inflammatory response in the arterial wall 
(Hansson, 2005). Adaptive immune responses 
that engage clonally expanded T cell populations 
contribute to this process, as do innate immune 
responses  that  are  mounted  by  macrophages 
and other cells. Several studies have suggested 
that components of low-density lipoprotein 
(LDL) particles trigger vascular inflammation 
(Tabas et al., 2007; Hartvigsen et al., 2009).
When LDL particles infiltrate the intima, 
they are prone to oxidative modification, caused 
by products of enzymatic activity of myeloper-
oxidase and lipoxygenases, as well as nonenzy-
matic oxidative reactions (Hevonoja et al., 2000). 
As  a  consequence  of  oxidation,  the  double 
bonds of fatty acid residues in phospholipids, 
cholesteryl esters, and triglycerides are cleaved, 
thus generating reactive aldehydes and trun-
cated lipids (Esterbauer et al., 1990). Among the 
latter, modified phospholipids, such as lyso-
phosphatidylcholine and oxidized 1-palmitoyl-
2-arachidonyl-sn-glycero-3-phosphocholine 
(ox-PAPC), induce endothelial cells, macro-
phages, and B1-type B cells to initiate innate 
immune responses, effecting adhesion molecule 
expression, chemokine production, and secre-
tion of natural antibodies containing germline 
IgM sequences (Leitinger et al., 1997; Binder 
et al., 2004; Gharavi et al., 2007).
The protein moiety of LDL can also undergo 
oxidative modification, whereby, for example,   
malondialdehyde (MDA) adducts, 4-hydroxy-
nonenal, and other molecular species form on 
lysyl residues of apolipoprotein B-100 (ApoB100) 
(Esterbauer et al., 1992). Antibodies are formed 
against MDA-lysine (Palinski et al., 1990) and 
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Immune responses to oxidized low-density lipoprotein (oxLDL) are proposed to be important 
in atherosclerosis. To identify the mechanisms of recognition that govern T cell responses to 
LDL particles, we generated T cell hybridomas from human ApoB100 transgenic (huB100tg) 
mice that were immunized with human oxLDL. Surprisingly, none of the hybridomas re-
sponded to oxidized LDL, only to native LDL and the purified LDL apolipoprotein ApoB100. 
However, sera from immunized mice contained IgG antibodies to oxLDL, suggesting that  
T cell responses to native ApoB100 help B cells making antibodies to oxLDL. ApoB100 
responding CD4+ T cell hybridomas were MHC class II–restricted and expressed a single T cell 
receptor (TCR) variable (V)  chain, TRBV31, with different V chains. Immunization of 
huB100tgxLdlr/ mice with a TRBV31-derived peptide induced anti-TRBV31 antibodies 
that blocked T cell recognition of ApoB100. This treatment significantly reduced athero-
sclerosis by 65%, with a concomitant reduction of macrophage infiltration and MHC class 
II expression in lesions. In conclusion, CD4+ T cells recognize epitopes on native ApoB100 
protein, this response is associated with a limited set of clonotypic TCRs, and blocking 
TCR-dependent antigen recognition by these T cells protects against atherosclerosis.
© 2010 Hermansson et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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After subcutaneous primary immunization with human 
oxLDL in CFA, followed by a booster injection in IFA, LN 
cells were collected and fused with thymoma cells to generate 
hybridomas. Of 268 growing hybridoma cultures, 117 expressed 
CD3 and CD4.
Monoclonal hybridomas were screened for their response 
to human oxLDL, native LDL, and purified unmodified 
ApoB100. T cell hybridoma activation was examined, as mea-
sured by IL-2 production after exposure to the putative anti-
gen in the presence of syngeneic, irradiated APCs. 48% of the 
hybridomas responded to native human LDL and ApoB100, 
but none recognized oxLDL (Fig. 1 A).
Based on TCR genotyping, 3 subgroups were identified 
among the clones that responded to native LDL and ApoB100 
(Table I and Table S1); a representative clone from each sub-
group (15–2, 45–1, and 48–5) is shown. There was a clear dose-
dependent response to unmodified ApoB100 (Fig. 1, B–D). 
Data from a clone with a different TCR genotype is shown for 
comparison in the online supplemental material; it recognized 
neither purified human ApoB100 nor recombinant ApoB100 
from transgenic mice (Fig. S1 A). To ensure that the response 
was not caused by a human-specific modification of ApoB100, 
hybridomas were also exposed to ApoB100 isolated from LDL 
of huB100tg x Ldlr/ mice. This recombinant ApoB100 also 
was recognized by the T cell hybridomas (Fig. 1, B–D). There-
fore, native LDL and ApoB100 contain epitopes that are rec-
ognized by these T cells.
T cells that react to native LDL and ApoB100  
express TRBV31
We characterized the TCRs of our T cell hybridomas by 
RT-PCR of the rearranged variable domains. The fusion part-
ner thymoma BW5147 expressed rearranged TRAV20 and 
TRBV12.1 variable chains, and all hybridomas expressed 
mRNA for these TCR chains. In addition, native human LDL- 
and ApoB100-specific T cell hybridomas uniformly expressed 
TCR TRBV31 (previously called TCR-V14; Table I and 
Fig. S2); no other V segment was identified (Table S1). In 
contrast, the reactive hybridomas used several families of V 
chains, including TRAV3 (hybridoma 15–2), 4 (45–1), and 
13 (48–5) (Table I). In unreactive hybridomas, V and V 
TCR chains were expressed in a nonrestricted fashion, not 
including TRBV31 (Table S1). For each LDL-responsive 
hybridoma, the surface expression of TRBV31 was confirmed 
by flow cytometry (Table I and Fig. S2 B). Interestingly, all 
TCR chains identified in these ApoB100 reactive hybridomas 
were previously identified in the aorta of atherosclerotic 
Apoe/ mice (Paulsson et al., 2000).
Oxidation of LDL extinguishes its recognition by T cells
We further analyzed the relationship between oxidation and 
the antigenicity of LDL particles by exposing T cell hybrid-
omas to LDL particles that were oxidized by copper for vari-
ous times, resulting in a range of oxidation (Fig. 1, E–G). For 
all T cell hybridomas, there was an inverse relationship be-
tween the degree of oxidation and the amplitude of activation 
other  oxidatively  generated  epitopes  of  LDL  particles 
(Ketelhuth et al., 2008). Such antibodies circulate in peripheral 
blood and are found in atherosclerotic lesions (Ylä-Herttuala 
et al., 1989; Zhou et al., 1998). In addition, circulating anti-
bodies have been identified that recognize a large number of 
peptide sequences in native ApoB100 (Fredrikson et al., 2003; 
Sjögren et al., 2008).
In contrast to the B1 cell-produced natural antibodies 
against oxidized phospholipids, antibodies to native and MDA-
modified ApoB100 are largely IgG molecules (Ylä-Herttuala 
et al., 1994; Fredrikson et al., 2007; Sjögren et al., 2008), 
implying that T cells activate isotype switching in the B cell. 
Although T cells recognizing components of oxidized LDL 
(oxLDL) have been identified both in hypercholesterolemic 
mice and among clones from human atherosclerotic lesions 
(Stemme et al., 1995; Nicoletti et al., 2000; Zhou et al., 
2006), the molecular properties of the T cell epitopes are 
poorly understood because of the biochemical complexity of 
the LDL particle and the oxidative process. This lack of knowl-
edge has hampered progress in our understanding of the 
mechanisms that regulate atherosclerosis and, as a result, in 
the development of immunotherapies.
To study T cell recognition of oxLDL, we created T cell 
hybridomas from human ApoB100 (huB100tg) transgenic mice 
that were immunized with oxLDL. These mice generate high 
levels of ApoB100 that is packaged into humanlike LDL parti-
cles (Linton et al., 1993). Similar to other transgenic mice that 
produce nonmurine proteins, huB100tg mice tolerate the or-
thologous transgene, neither producing antibodies to it nor de-
veloping spontaneous autoimmune disease. Based on previous 
studies, we had expected that they would respond to immuni-
zation by mounting cellular and humoral immune responses 
toward oxidation-induced epitopes on the LDL particles.
Unexpectedly, oxLDL–immunized huB100tg mice devel-
oped T cell responses against native LDL and purified ApoB100. 
The responding T cells were MHC class II–restricted CD4+ 
cells and expressed TCRs that contained the variable  do-
main TRBV31. Abrogation of TRBV31+ T cells attenuated 
the cellular immune response to ApoB100, and immuniza-
tion of hyperlipidemic mice against TCR TRBV31 inhibited 
the development of atherosclerosis. These results strongly 
suggest that autoimmune T cells that recognize protein epi-
topes from native ApoB100 promote atherosclerosis.
RESULTS
T cell hybridomas generated after immunization  
with oxidized LDL recognize native LDL and ApoB100
We used huB100tg mice to characterize the T cell response to 
oxLDL. These mice express full-length human ApoB100 in 
the liver and gut and harbor humanized lipoprotein profiles. 
The huB100tg model permits the use as antigen of human 
oxLDL, the immunogenic epitopes of which have been care-
fully characterized. This model makes it possible to study cel-
lular immune responses to human LDL-derived epitopes in a 
controlled model system and with easy access to large amounts 
of antigen for purification and characterization.JEM VOL. 207, May 10, 2010 
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MDA exposure of the lipoprotein particles, similar to the find-
ing for copper oxidized LDL (Fig. 2 A). Of note, a dose de-
pendent response could be detected against MDA modified 
LDL particles at any given concentration but its amplitude 
was inversely proportional to the extent of modification of 
the particles (Fig. 2, A and B). Similar findings were made for 
copper-oxidized LDL (Fig. 2 B).
To exclude an antigen-independent, detrimental effect of 
oxLDL on T cell activation, we examined its effect on T cells 
activated by ApoB100, native LDL, OVA, or the polyclonal 
T cell mitogen, Concanavalin A. The T cell hybridoma 
(Figs. 1, E-G, and Fig. 2 A). Thus, native LDL induced the 
strongest IL-2 response, whereas heavily oxidized LDL did 
not trigger activation.
In another set of experiments, LDL was modified by 
MDA adduct formation. MDA is formed during lipid perox-
idation and reacts with free amino groups in ApoB100 to 
generate MDA-lysine and other modified residues (Fogelman 
et al., 1980, Haberland et al., 1988, Hamberg et al., 1974). 
Therefore, it can be considered as a chemically defined 
oxidative modification of LDL. MDA modification reduced 
T cell recognition of LDL proportionally to the extent of 
Figure 1.  T cell hybridomas recognize 
native LDL and its ApoB100 protein.  
(A) 105 hybridoma cells from each of 23 dif-
ferent clones were incubated with 4 × 105 
irradiated APCs with 20 µg /ml of LDL, oxLDL, 
or ApoB100. Each column represents one 
clone. Media without LDL were used as nega-
tive controls. Results are from one experi-
ment. (B–D) 105 hybridoma cells of three 
different clones (B, hybridoma 15–2; C, 48–5; 
D, 45–1) were incubated with 4 × 105 irradi-
ated APCs and different concentrations of 
purified human ApoB100 from plasma LDL,  
or transgenic human ApoB100 from  
huB100tg x Ldlr/ mice. Hybridomas 15–2, 
48–5, and 45–1 (B–D) recognize purified and 
transgenic ApoB100 in a dose-dependent 
manner. In all experiments, IL-2 secretion was 
used as a measure of activation. Data show 
means ± SEM. Results are representative of 
three independent experiments. (E–G) 105 
hybridoma cells were incubated with 4 × 105 
irradiated APCs with 20 µg/ml of LDL or LDL 
oxidized to different extents (copper oxida-
tion [20 µM CuSO4] for varying lengths  
of time). After 24 h of incubation with  
the different preparations, IL-2 secretion  
was measured in the supernatant. X axis 
shows the mean of TBARS values and y axis 
shows the mean of IL-2 levels. All T cell 
hybridomas showed an inverse correlation 
between IL-2 levels and the degree of LDL 
oxidation. Results are representative of three 
independent experiments.
Table I.  TRAV and TRBV expression on reactive clones
Clone PCR Flow cytometry
V gene V gene Anti- 
TRAV14
Anti- 
TRAV12
Anti- 
TRBV31
Resulting phenotype
15-2 TRAV14, 3 and 20 TRBV31 and 12.1 negative — positive TRAV3/TRBV31
45-1 TRAV4 and 20 TRBV31 and 12.1 — — positive TRAV4/TRBV31
48-5 TRAV12, 13 and 20 TRBV31 and 12.1 — negative positive TRAV13/TRBV31
The cDNA from reactive clones was amplified by PCR using appropriate V-specific 5 primers with a constant region C 3 primer, or relevant V-specific 5 primers with a 
constant region C 3 primer (Tables S1 and S2). Further phenotype of V and V chain expression was analyzed by flow cytometry using antibodies to TRAV14, TRAV12, 
and TRBV31.1084 T cell response to native LDL | Hermansson et al.
mice that carry a transgenic TCR recognizing OVA and are 
therefore activated by OVA in the context of MHC class II 
(Fig. 2, A and C). T cell viability was unaffected by oxLDL at 
the concentrations that were used in this study (Fig. S3). Col-
lectively, these data suggest that T cell recognition of LDL is 
gradually extinguished by LDL oxidation.
T cell responses to native LDL and ApoB100  
are I-Ab restricted
Because purified ApoB100 induced activation of the CD4+ 
T cell hybridomas, we hypothesized that the epitopes are pep-
tides that are presented by MHC class II—in our mice, the I-Ab 
haplotype. When we added an antibody to block I-Ab on APC, 
T cell activation was suppressed in all clones. Mismatched, I-Ad–
expressing APCs from BALB/c mice failed to present ApoB100 
to antigen-specific T cell hybridomas (Fig. 3).
Cellular immune responses can also be triggered by lipid 
antigens after presentation by CD1. Because ApoB100 asso-
ciates with lipids in the LDL particle, we measured T cell re-
sponses to ApoB100 that was presented by I-Ab–bearing APCs 
that lacked CD1d, the only CD1 molecule that is expressed 
in mice. CD1d-deficient APCs, however, did not impair the 
response (Fig. S1). Similarly, APCs from I-Ab mice that lacked 
MHC class I molecules presented ApoB100 antigens to T cell 
hybridomas (Fig. S1). These results show that ApoB100 anti-
gen is recognized by MHC class II–restricted CD4+ T cells.
The cellular immune response to native ApoB100  
is preserved in polyclonal T cell populations
Having established that atherosclerotic lesions contain oligo-
clonal T cells (Paulsson et al., 2000) and observing that hybrid-
omas from mice that are immunized with oxLDL recognize 
native ApoB100, we asked whether such autoimmune re-
sponses occur in polyclonal T cell populations. This hypothesis 
was tested in huB100tg x Ldlr/ mice, which develop signifi-
cant hypercholesterolemia with high plasma levels of LDL con-
taining human ApoB100, even on a chow diet. These mice 
were immunized with oxLDL or native ApoB100, followed by 
in vitro challenge of splenocytes from these mice with oxLDL 
or native ApoB100.
As before, native ApoB100 elicited the highest proliferative 
T cell response, whereas highly oxidized LDL did not trigger 
activation, as registered by DNA synthesis. This activation pat-
tern was similar in oxLDL- and ApoB100-immunized mice 
(Fig. 4 ). In contrast, antibody responses were detected against 
oxLDL, native LDL, and ApoB100 (Fig. 4 B). Consequently, 
T cell responses to native ApoB100 may help B cells produce 
antibodies to a variety of epitopes on oxidized as well as native 
LDL epitopes. T cell responses to native ApoB100 were not 
detectable in spleen cell preparations from nonimmunized 
mice, possibly because of limited sensitivity of the assay, thus 
expansion of autoreactive T cell clones by immunization with 
ApoB100 was necessary to detect a response (Fig. S4).
Similar to the findings in huB100tg x Ldlr/ mice, immu-
nization of Apoe/ mice with native murine LDL elicited 
a T cell response to the native LDL particles, indicating that 
recognizing  native  LDL  and  ApoB100  was  less  activated 
when increasing concentrations of oxLDL were added to the 
culture, but showed unchanged activation levels when coin-
cubated with Concanavalin A (Fig. 2 C). Unchanged activa-
tion of T cells was also seen when using cells from OT-II 
Figure 2.  T cell recognition of LDL is decreased by oxidative modi-
fication. 105 hybridoma cells (48–5) were coincubated with 4 × 105 ir-
radiated APCs. (A) 20 µg/ml of LDL or LDL modified to different extents 
(malondialdehyde [MDA] or copper oxidation [20 µM CuSO4] for varying 
lengths of time) was added to the coincubation, and 24 h later IL-2 secre-
tion was measured in the supernatant. Filled columns show response to 
native LDL and striped columns show response to medium control.  
(B) Dose–response curves for the coincubation with different concentra-
tions of LDL-modified either with MDA or copper. (C) Co-incubation with 
fixed concentrations of ApoB100, native LDL, or concanavalin A together 
with increasing concentration of copper-oxidized LDL. For OVA, co- 
incubations were done with splenocytes from OT-II mice and activation 
was measured as CPM from [3H]thymidine incorporation, as described in 
the Materials and methods section. Data show means ± SEM. Results are 
representative of three independent experiments.JEM VOL. 207, May 10, 2010 
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nization of huB100tg x Ldlr/ mice. This treatment induced 
the production of antibodies specific for the TRBV31 se-
quence (Fig. 5 B). Circulating IgG antibodies from immu-
nized mice bound to LDL-reactive TRBV31+ hybridomas 
(Fig. 5 C), but not to nonreactive TRBV31 negative hybrid-
omas (Fig. 5 D), and the addition of IgG from TRBV31 
peptide-immunized mice inhibited T cell hybridoma activa-
tion in response to ApoB100 (Fig. 5 E). Thus, immunization 
of huB100tg x Ldlr/ mice with TRBV31 peptide induced 
the production of blocking antibodies that prevented TCR 
TRBV31 from recognizing LDL protein. We observed sig-
nificantly reduced levels of TRBV31 mRNA in aorta and 
spleen at sacrifice (Fig. 5 F), possibly because antibodies bind-
ing to their TCR interfered with the expansion of TRBV31+ 
T cells.
Immunization against TRBV31+ peptide reduces 
atherosclerosis
Finally, we examined the role of TRBV31+ T cells in athero-
sclerosis. HuB100tg x Ldlr/ mice, which develop spontane-
ous atherosclerosis, were immunized against TRBV31. This 
led to a 65% reduction in lesion size in the aortic root compared 
such responses were not limited to the huB100tg model (un-
published data).
Depletion of TRBV31+ T cells reduces the proliferative 
response to ApoB100
Because  all  LDL  responding  T  cell  hybridomas  expressed 
TRBV31, we surmised that this TCR V chain is required for 
the recognition of ApoB100. To test this hypothesis, we 
immunized mice with ApoB100, isolated splenocytes, and re-
moved TRBV31+ T cells by FACS. These steps blunted the 
response against ApoB100 on in vitro challenge.
No such effect was observed when T cells that expressed a 
different variable chain, TRBV19, were depleted from spleno-
cytes (Fig. 5 A). Therefore, a significant portion of the cellular 
immune response to ApoB100 in this model is fulfilled by 
TRBV31+ T cells.
Immunization against TRBV31 peptide inhibits T cell 
recognition of ApoB100
To inhibit T cell responses to LDL protein, we synthesized a 
peptide from TRBV31 including its CDR2 domain, fused it 
to KLH carrier protein, and used the preparation for immu-
Figure 3.  T cell responses to ApoB100 are I-Ab–restricted. 105 hybridoma cells were incubated with 4 × 105 irradiated APCs from mice of either the 
I-Ab or I-Ad haplotype and different concentrations of human ApoB100. Hybridoma cells were also challenged with ApoB100 in the presence of a blocking 
antibody to MHC class II (I-Ab). After 24 h of incubation, IL-2 secretion was measured in the supernatant. A, 15–2 clone; B, 48–5 clone; C, 45–1 clone. 
Data show means ± SEM. Results are from one experiment.
Figure 4.  Immunization with oxLDL or ApoB100 expands T cell populations that recognize native epitopes of LDL and induces antibodies to 
oxLDL, native LDL, and ApoB100. huB100tg x Ldlr/ mice were immunized with oxLDL (A) or ApoB100 (B). 5  105 splenocytes were challenged in 
vitro with 20 μg/mL of human oxLDL or native human ApoB100. Error bars represent the mean ± SEM of the stimulation index from [3H]thymidine  
incorporation, as described in the Materials and methods. Sera were assayed for antibodies to oxLDL, native LDL, and ApoB100. Values are expressed as 
mean ± SEM of the OD values for each dilution. Data are representative of two independent experiments (n = 4 mice per group). **, P < 0.01.1086 T cell response to native LDL | Hermansson et al.
We observed substantially reduced inflammation, accompa-
nied by decreased expression of MHC class II protein I-A 
(Fig. 7 B). Furthermore, aortic mRNA for the chemokine, 
CCL2 (monocyte chemoattractant protein-1) was signifi-
cantly reduced in peptide immunized mice, whereas CCL5 
(RANTES) mRNA was unchanged (Fig. 7, D and E). In 
summary, abrogation of TCR TRBV31 recognition of native 
ApoB100 reduces vascular inflammation and inhibits the de-
velopment of atherosclerosis.
DISCUSSION
In this study, we have identified a cellular immune response 
to ApoB100 protein of native LDL, and show that this re-
sponse plays an important role in atherosclerosis. T cells from 
with control mice that were immunized with carrier protein 
(Fig. 6 A). Lesion size was uniformly reduced in cross sec-
tions of the proximal aorta of TRBV31-immunized mice, 
without any detectable change in lesion distribution (Fig. 6 A). 
Lesions were also analyzed after Sudan IV staining of lipid le-
sion area in en face preparations of the aortic arch (Fig. 6 B). 
Here, TRBV31 immunization led to a 57% reduction in 
lesion area.
Plasma cholesterol, triglycerides, ApoB100 levels, and li-
poprotein profiles were unchanged (Fig. S5), as well as anti-
body titers to LDL and oxLDL (unpublished data).
Immunohistochemistry of the lesions showed that macro-
phage levels were reduced by 50% (Fig. 7 A), whereas no sig-
nificant effect was registered on T cell infiltration (Fig. 7 C). 
Figure 5.  TRBV31+ T cells recognize ApoB100.  
(A) Depletion of TRBV31+ cells reduces T cell responses to 
ApoB100. HuB100tg x Ldlr/ mice were immunized with 
ApoB100. Splenocytes, harvested after a booster injection, 
were depleted of TRBV31+ or TRBV19+ cells by fluores-
cence-activated cell sorting. 5 × 105 TRBV31+/TRBV19 or 
TRBV19+/TRBV31 cells were challenged in vitro with 
different concentrations of human ApoB100. T cell activa-
tion was measured by [3H]thymidine incorporation and 
stimulation index, calculated as described in the Materials 
and methods section. Data show means ± SEM and are 
representative of two experiments. *, P < 0.05. (B) Induc-
tion of IgG antibodies to TRBV31 peptide after immuniza-
tion with TRBV31. HuB100tg x Ldlr/ mice were 
immunized and boosted with TRBV31 peptide conjugated 
to KLH, or with KLH alone as control. Serum IgG anti-
bodies to TRBV31 peptide were measured by ELISA. Results 
are presented as mean ± SEM and representative of two 
independent experiments. **, P < 0.01; ***, P < 0.001.  
(C) Anti-TRBV31 IgG binds to LDL-reactive T cell hybrid-
oma. Affinity-purified IgG antibodies from TRBV31- 
immunized mice were incubated with an LDL-reactive 
TRBV31+ hybridoma (48–5 clone), followed by incubation 
with FITC-labeled anti–mouse IgG and flow cytometric 
analysis. The graph shows representative histograms from 
48–5 cells in the FITC channel (MFI, x axis) after labeling 
with IgG from mice immunized with the TRBV31-KLH 
conjugate (gray profile) or KLH alone (dashed line). Total IgG 
from untreated mice was used as negative control (black 
line). Results are representative of three independent  
experiments. (D) Anti-TRBV31 IgG does not bind to a non 
LDL-reactive T cell hybridoma. Affinity-purified IgG anti-
bodies from TRBV31-immunized mice were incubated 
with a non–LDL-reactive hybridoma (97–3 clone), fol-
lowed by incubation with FITC-labeled anti–mouse IgG 
and flow cytometric analysis. The graph shows represen-
tative histograms from 97–3 cells in the FITC channel 
(MFI, x axis) after labeling with IgG from mice immunized 
with the TRBV31-KLH (gray profile) conjugate (dashed line) or KLH alone. Total IgG from untreated mice was used as negative control (black line). Results 
are representative of three independent experiments. (E) Anti-TRBV31 IgG inhibits T cell recognition of ApoB100. 104 48–5 hybridoma cells were chal-
lenged in vitro with 20 µg /ml ApoB100 in the presence of 4 × 104 irradiated APCs with IgG from mice immunized with TRBV31-KLH or KLH alone. After 
24 h of incubation, IL-2 secretion was measured in the supernatant. Results show means ± SEM and are representative of three independent experiments.   
*, P < 0.05. (F) Immunization against TRBV31 reduces TRBV31 TCR mRNA in spleen and aorta. mRNA transcript levels were evaluated in aorta and spleen 
from huB100tg x Ldlrl/ mice immunized with TRBV31-KLH conjugate or KLH alone. Bar graphs represent the mean ± SEM of TRBV31 mRNA relative to 
HPRT mRNA/CD3 mRNA relative to HPRT mRNA (n = 9 mice per group). *, P < 0.05. Results were pooled from two experiments.JEM VOL. 207, May 10, 2010 
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1992; Stemme et al., 1995). These responses have clearly been 
underestimated by us and others. Our present data do not 
rule out the existence of oxLDL-reactive T cells, but demon-
strate the presence and pathogenetic role of T cells recogniz-
ing native ApoB100 epitopes.
The cellular immune response to LDL that we observed 
was mounted by CD4+ T cells and showed MHC class II re-
striction. In conjunction with data that demonstrate that 
purified ApoB100 protein elicits an identical response to that 
of intact LDL, our results strongly suggest that intracellular 
processing of ApoB100 in the APC generates oligopeptide 
epitopes that are recognized by the T cells as peptide-MHC 
complexes. The finding that I-Ab is required for the T cell 
response and cannot be substituted by another MHC class II 
molecule or by CD1d further supports the model that spe-
cific oligopeptides that are bound to MHC class II constitute 
the ligand with which clonotypic TCRs interact.
Interestingly, among the peptides that have been eluted 
from I-Ab on B cells and macrophages, several are derived 
from unmodified ApoB100 (Dongre et al., 2001). Moreover, 
among HLA-DR molecules isolated from human APCs 
grown under standard cell culture conditions, a high propor-
tion carry ApoB100 oligopeptides in their antigen-presenting 
grooves (Urban et al., 1994). These observations suggest that 
ApoB100 oligopeptides associate with certain MHC class II 
molecules. Because APCs can present ApoB100 epitopes, 
there should be a significant risk for autoimmune reactions 
oxLDL-immunized mice recognize unmodified ApoB100 
from native LDL rather than oxLDL. This response is clono-
typic and involves TRBV31+ TCR, and immunization against 
this T cell receptor significantly reduces atherosclerosis.
OxLDL triggers a strong humoral immune response that 
generates antibodies to oxidation-induced epitopes on LDL 
particles (Palinski et al., 1989, 1996). Because T cell–depen-
dent antibodies form against aldehyde adducts on ApoB100 
(Steinbrecher et al., 1984; Fredrikson et al., 2003) and expo-
sure of APC-T cell cultures to oxLDL activates CD4+ T cells 
(Frostegård et al., 1992; Stemme et al., 1995), T cells have 
been assumed to selectively recognize epitopes on ApoB100 
that are generated by oxidation of the native apolipoprotein.
To the contrary, we have found that T cells from oxLDL-
immunized mice preferentially recognize motifs from native 
LDL. These epitopes are components of native ApoB100 and 
the T cell reactivity toward them is extinguished rather than 
induced by oxidative modification of LDL. Although we 
cannot rule out that nominally native LDL preparations may 
contain oxidized structures even in the presence of anti-
oxidants, the finding that purified, delipidated ApoB100 pro-
tein induced similar T cell responses as native LDL supports 
the notion that the epitopes inducing these responses were 
present in the native ApoB100 protein of LDL.
When  reanalyzing  data  published  previously,  we  have 
noticed that T cell reactivity to native LDL was registered for 
plaque clones as well as peripheral blood (Frostegård et al., 
Figure 6.  Immunization against TRBV31 reduces atherosclerosis. HuB100tg x Ldlr/ mice were immunized with the TRBV31 peptide-KLH conjugate 
or with KLH alone. The mice were sacrificed after 10 wk on a Western diet. (A) Atherosclerotic lesion size in the proximal aorta. Lesions were analyzed by 
microscopic morphometry of serial sections at 100–800 µm from the aortic valves. Data show cross-sectional lesion size (mm2). Inset shows means of the 
eight cross-sectional lesion sizes for each animal, and the line indicates mean value per group of mice. n = 9 mice per group. Pooled data are presented 
from two independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Representative micrographs from immunized mice. Hematoxylin-Oil red O 
staining, original magnification 20×. White arrows indicate lesion areas. Bars, 250 µm. (B) Atherosclerotic lesion size in the aortic arch. Dissected arches 
were stained with Sudan IV en face and the percentage lesion area of total vessel area was calculated using ImageJ image analysis software. The additive 
area of all the plaques in a given aortic arch was calculated as a percentage of the total surface area of the arch. n = 8 mice per group. Two representa-
tive stained samples from each group are shown. *, P < 0.05.1088 T cell response to native LDL | Hermansson et al.
These cells internalize modified LDL particles through scav-
enger receptors and can secrete the immunosuppressive cyto-
kines IL-10 and TGF- (Mills et al., 2000; Bouhlel et al., 
2007). Furthermore, LDL that enters the scavenger receptor 
pathway carries ligands for antiinflammatory PPAR tran-
scription factors (Li and Glass, 2007). Therefore, the milieu at 
the sites of antigen accumulation can inhibit activation of 
LDL-reactive T cell clones.
In  addition,  regulatory  T  cells  regulate  atherosclerosis 
(Ait-Oufella et al., 2006) by dampening disease progression 
and by inhibiting LDL-reactive Th1 cells (Klingenberg et al., 
2010). If regulatory T cells are preferentially induced when 
endogenous LDL is presented to T cells, peripheral tolerance 
would be maintained. Interestingly, expression of proteins in 
the liver, where LDL is produced, promotes induction of 
T reg cells and peripheral tolerance to autoantigen (Lüth 
et al., 2008).
Parenteral administration of LDL in a proinflammatory 
adjuvant can break such tolerance, because oxidized particles 
are amenable to scavenger receptor-mediated uptake into APCs 
to LDL. Systemic reactions such as these present an obvious 
threat, because LDL is present throughout the circulatory 
system and in all organs. We have assumed that all ApoB100-
reactive T cell clones are deleted in the thymus during 
development, i.e., that autoimmunity is avoided by cen-
tral tolerance.
Our current data, however, rule out this possibility, as we 
identified a T cell population that reacts to native ApoB100. 
Consistent with these results, it has been suggested that   
the immune system is not tolerized to all peripheral auto-
antigens and that the existence of autoreactive T cells, per se, 
does not place the healthy individual at risk for autoimmunity 
(Kyewski and Klein, 2006). Consequently, ApoB100-reactive 
T lymphocytes most likely constitute part of the peripheral 
cell repertoire.
If autoreactivity is not eliminated by central tolerance dur-
ing development, autoimmune reactions must be avoided by 
peripheral tolerance mechanisms, which could rely on active 
inhibition of autoreactivity; e.g., by cells that secrete immuno-
regulatory cytokines, such as M2 macrophages (Gordon, 2003). 
Figure 7.  Immunization against TRBV31 reduces inflammation in atherosclerotic lesions. (A) Reduced accumulation of macrophages in lesions of 
TRBV31-immunized mice. Images show CD68 immunostaining of representative aortic root sections from mice immunized with KLH alone (left) or the 
TRBV31-KLH conjugate (right). The dot plot shows proportion of total lesion area stained by CD68 antibody in the two groups. Data show values for indi-
vidual mice and mean value for each group (line; n = 8 mice per group). (B) Reduced MHC class II (I-Ab) expression in lesions of TRBV31-immunized mice. 
Images show I-Ab immunostaining of representative sections from the aortic root. The dot plot shows the number of I-Ab+ cells per mm2 lesion area in 
the two groups (n = 8 mice for KLH and 9 mice for TRBV31). (C) No change in CD3 expression in lesions of TRBV31-immunized mice. Images show CD3 
immunostaining of representative sections from the aortic root. The dot plot shows the number of CD3+ cells per square millimeter of lesion area in the 
two groups (n = 7 mice for KLH and 8 mice for TRBV31). n.s., not significant. Immunoperoxidase labeling, original magnification 100×. Bars: (A–C) 100 
µm. (D–E) Immunization with TRBV31 reduces CCL2 mRNA. mRNA levels of CCL2 and CCL5 were measured by real-time RT-PCR in aorta from huB100tg x 
Ldlr/ mice immunized with TRBV31-KLH conjugate or KLH alone. Error bars represent the mean ± SEM for mRNA under study/mRNA for the house-
keeping gene, HPRT (n = 9 mice per group). *, P < 0.05 in A–D. Results in A–E show pooled data from two experiments.JEM VOL. 207, May 10, 2010 
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cells that recognize lipid antigens that are presented via CD1, 
CD8+ T cells that recognize MHC class I–restricted antigens, 
and B cells.
Immunization of atherosclerosis-prone huB100tg x Ldlr/ 
mice with TRBV31 peptide provided important insights into 
the  immunopathology  of  atherosclerosis.  Antibodies  that 
were isolated from hyperimmune sera blocked activation of 
T cells in response to ApoB100, and elimination of TRBV31+ 
cells by flow cytometry reduced T cell responses to ApoB100 
in splenocyte cultures.
The induction of anti-TRBV31 antibodies in huApo-
B100tg x Ldlr/ mice reduced vascular inflammation and was 
accompanied by a prominent, 65% reduction in atherosclerosis 
in the aortic root, and 57% in the arch. Thus, our data strongly 
suggest that a subset of T cells that recognize ApoB100 epit-
opes regulate the development of atherosclerosis. Reduction 
of lesion size was accompanied by reduced MHC class II, 
CCL2 chemokine, and macrophages in lesions, therefore in-
hibition of the T cell response to ApoB100 likely reduced 
inflammation in the lesions. Our findings thus confirm and 
extend previous reports showing an important role for CD4+ 
T cells and their restriction element, MHC class II, in athero-
sclerosis (Huber et al., 2001; Zhou et al., 2006). In line with 
this notion, mice carrying different MHC haplotypes differ in 
their susceptibility to atherosclerosis (Schulte et al., 2008).
The conditions during activation of naive T cells, includ-
ing the phenotype of antigen-presenting cells, presence of 
co-stimulatory factors, local cytokines, and, when immuniza-
tion protocols are used, type of adjuvant, determine the dif-
ferentiation of activated T cells into effector phenotypes 
(Lu and Rudensky, 2009). Therefore, preexisting, ApoB100-
reactive CD4+ T cells may differentiate into proatherogenic 
Th1 cells or atheroprotective regulatory T cells depending on 
local conditions in the plaque and draining LNs during im-
munization (Andersson et al., 2010; Wigren et al., 2009).
The use of the huB100tg x Ldlr/ model permitted us to 
study human LDL-derived epitopes to dissect the cellular au-
toimmune response in atherosclerosis. Our data 
(Nicoletti et al., 1999) and because the local production of 
proinflammatory cytokines can counteract the effects of im-
munoregulatory cytokines. Similar conditions could exist in 
the developing atherosclerotic lesion, where accumulation of 
LDL is followed by uptake into macrophages and dendritic 
cells in a proinflammatory environment (Zhou et al., 2006).
A modest extent of oxidation may enhance entry of the 
LDL particle into the antigen-presenting pathway (Fig. 8). 
This would result in binding of ApoB100-derived oligopep-
tides to MHC class II molecules and presentation of such 
complexes on the APC surface. Our data show that T cells 
recognize this type of native ApoB100 epitopes, but also pro-
vide help to B cells that produce antibodies to native and oxi-
datively induced structures on LDL. In this scenario, modest 
oxidation would increase antigen uptake; survival of native, 
i.e., nonmodified peptide epitopes would be necessary for 
T cell recognition; and extensive oxidation would eliminate 
T cell–dependent immune reactions to the LDL particle.
Our data implicate TCR TRBV31-expressing CD4+ T 
cells that recognize native ApoB100 as proatherogenic. Our 
results, however, do not rule out the possibility that the oxi-
dative changes to LDL in vivo may differ from those that are 
induced by copper or MDA. Among the defined adducts to 
the polypeptide chain that are formed during lipid peroxida-
tion, we examined only carbonyls (such as MDA), therefore we 
cannot rule out that other more physiological modification 
pathways, i.e., by HOCl, chloramines, phenoxyl radical in-
termediates, peroxynitrite (ONOO-), and myeloperoxidase-
dependent nitrogen dioxide (NO2) production (Berliner and 
Heinecke, 1996), which may contribute to T cell recognition.
Furthermore,  our  hybridoma  strategy  detailed  a  small 
subset of cells, and certain reactivities may not have been 
represented in the hybridoma repertoire that was analyzed. 
Finally, our strategy focused on antigens that were presented 
to CD4+ T cells by professional APCs through the endocytic, 
MHC class II–restricted pathway. Additional important con-
tributions to LDL immunoreactivity may arise from NKT 
Figure 8.  Proposed hypothesis for CD4+ T cell 
recognition of LDL. LDL particles are taken up by LDL 
receptors and, if modified, by scavenger receptors on the 
APC. Uptake could also be mediated by Fc receptors li-
gating opsonized LDL particles. After endosomal degra-
dation, peptides derived from ApoB100 are transferred 
into the antigen-presenting pathway, where they bind to 
nascent MHC class II molecules. The peptide–MHC com-
plexes are transported to the cell surface and recognized 
by CD4+ T cells equipped with TRBV31+ TCR. The ensuing 
T cell activation leads to cytokine secretion that can pro-
mote macrophage activation and inflammation. Once T 
cells are activated toward native ApoB100 epitopes, they 
may provide help for B cells recognizing native LDL, 
ApoB100, or lipids such as phosphocholine (PC), but also 
oxidatively modified epitopes such as MDA-ApoB100 or 
oxPC. T, T cells; B, B cells; blue symbol, Scavenger recep-
tors or Fc receptors; red symbol, LDL receptors.1090 T cell response to native LDL | Hermansson et al.
cDNA using Superscript II (Invitrogen) with random hexanucleotide prim-
ers (pdN6) in the presence of RNasin (Life Technologies). The cDNA was 
amplified using appropriate V family specific 5 primers with a constant re-
gion C 3 primer, or relevant V family– specific 5 primers with a con-
stant region C 3 primer (Table S2).
The nomenclature of the international immunogenetics information 
system (IMGT) was used to designate TCR-V chain use of T cells. All 
TCR  V-chain sequences were extracted from the IMGT database (http://
imgt.cines.fr/; Lefranc et al., 2003). For correspondence between old and new 
nomenclatures,  see  http://imgt.cines.fr/textes/IMGTrepertoire/LocusGenes/
nomenclatures/human/TRB/TRBV/Hu_TRBVnom.html.
The mastermix for the PCR reactions contained 10 mM Tris-HCl, 
50 mM KCl, 1.5 mM MgCl2, 1 mM dNTP, and 0.2 U/ml Taq polymerase 
(Invitrogen). All primers were added to a final concentration of 0.2 µM. The 
reactions were performed for 35 cycles at 94°C (40 s) for denaturation, 58°C 
(40 s) for annealing, and 72°C (1 min) for polymerization. The PCR products 
were analyzed on a 1.5% agarose gel and visualized by GelRed staining.
MHC restriction assay. To evaluate MHC class II restriction, we incu-
bated 105 hybridoma cells with different concentrations of ApoB100 in the 
presence of 4 × 105 irradiated (1.6 Gy) APCs from syngeneic (C57BL/6; 
I-Ab) or allogeneic (BALB/c; I-Ad) donors.
In a separate experiment, 105 hybridoma cells were incubated with 
ApoB100 in the presence of 4 × 105 irradiated (1.6 Gy) APC from syngeneic 
donors in the presence or absence of blocking antibodies to MHC class II 
(BD). In both experiments, T cell activation was defined by increases in IL-2 
concentration in the supernatant.
Lipoprotein preparations. LDL (d = 1.019  1.063 g/ml) was isolated by 
ultracentrifugation from pooled plasma of healthy donors, as previously de-
scribed (Havel et al., 1955). 2 mM benzamidine, 0.5 mM PMSF, and 0.1 U/
ml aprotinin were added immediately after the plasma was prepared. After iso-
lation, LDL was dialyzed extensively against PBS. 1 mM EDTA was added to 
an aliquot of LDL to generate unmodified LDL. Using the same procedure, 
recombinant LDL was prepared from plasma of huB100tg x Ldlr/.
Highly oxidized LDL was obtained by incubating 1 ml of LDL (1 mg/ml 
protein content, determined by Bradford assay’ Bio-Rad Laboratories) in the 
presence of 20 µM CuSO4 for 18 h at 37°C; different degrees of oxidation 
were obtained by incubating LDL with 20 µM CuSO4 for 1, 2, 4, or 8 h. 
The extent of oxidation was evaluated by TBARS, as previously described 
(Puhl et al., 1994).
Preparation of soluble ApoB100. ApoB100 was isolated by using a 
modification of previously described methods (Steele and Reynolds, 1979; 
Wessel and Flügge, 1984). In brief, 0.4 ml methanol, 0.1 ml chloroform, and 
0.3 ml water were added to 0.1 ml of LDL (1 mg/ml); the suspension was 
then vortexed and centrifuged at 9,000 g for 1 min. The upper phase was re-
moved and 0.3 ml of methanol added to the lower phase and interphase with 
precipitated protein, which was mixed again and centrifuged at 9,000 g for 
2 min to pellet the protein.
To obtain soluble and pure ApoB100, the protein pellet was resus-
pended in a minimum volume of 10% SDS (Bio-Rad Laboratories) until it 
solubilized. These preparations first were filtered on a PD-10 column (GE 
Healthcare) to remove excess SDS. They were then purified on a Superdex-
200 size-exclusion column (0.5 ml/min, in Tris-HCl, pH 7.4). ApoB100 
preparations were greater than 90% pure, as evaluated in a second injection 
into a Superdex-200 column (GE Healthcare) and analyzed on SDS-PAGE 
(Fig. S6). Finally, protein concentration was determined by Bradford assay 
(Bio-Rad Laboratories).
Flow cytometric analysis of TCR V domain expression. Commer-
cially available anti-mouse TCR-V and TCR-V mAb (BD) were used to 
detect TCR-V and TCR-V. They were combined with anti-CD3-
Pacific Blue and anti-CD4-APC to stain T cell hybridomas. Splenocytes from 
unimmunized mice were used as positive controls for all antibodies. The 
cells were analyzed on a CyAn ADP flow cytometer (Dako).
demonstrate that clonotypic T cells that recognize ApoB100 
are needed for the development of advanced atherosclerosis. 
Future work should address whether the immunopathology   
of human atherosclerosis is similar to that of our model and eval-
uate a TCR-directed immunomodulatory strategy for the treat-
ment or prevention of atherosclerotic cardiovascular disease.
MATERIALS AND METHODS
Animals and immunization. We used 7-wk-old male human ApoB100 
transgenic mice, huB100tg (C57BL/6,129-Apobtm2Sgy; DNX Transgenics), 
to generate T cell hybridomas. These mice carry the full-length human 
APOB100 gene, in which codon 2153 has been converted from leucine to 
glutamine to prevent the formation of ApoB48, generating only ApoB100 
(Linton et al., 1993; Boren et al., 1998). They were first immunized s.c. with 
50 µg of copper-oxidized human LDL in CFA, and were boosted after 2 wk 
with 50 µg oxLDL in IFA.
To evaluate the role of TRBV31+ T cells in disease development, we 
used same strain crossed with the Ldlr/ (C57BL/6,129-Apobtm2SgyLdlrtm1Her 
(Skålén et al., 2002; provided by J. Borén, Göteborg University, Göteborg, 
Sweden) as they develop large atherosclerotic lesions, even on a normal 
chow diet, permitting quantitative studies of disease. Both strains have the 
same  I-Ab+  MHC  haplotype  and  both  strains  react  to  native  LDL  and 
ApoB100. 11-wk-old male huB100tg x Ldlr/ mice were immunized s.c. 
with 100 µg TRBV31 peptide conjugated to KLH and emulsified in CFA 
and boosted 4 wk later with the same antigen emulsified with IFA. Control 
mice were immunized s.c. with 100 µg KLH.
The mice were fed a high-fat diet (maize starch, cocoa butter, casein, 
glucose,  sucrose,  cellulose  flour,  minerals,  and  vitamins;  17.2%  protein,   
21% fat [62.9% saturated, 33.9 unsaturated and 3.4% polyunsaturated], 0.15% 
cholesterol, 43% carbohydrates, 10% H2O, and 3.9% cellulose fibers; R638) 
starting 5 d after the immunization until sacrifice 10 wk later with CO2. The 
TRBV31 peptide includes the CDR2 variable region of the TCR  chain 
(amino acid residues 45–62, “ATGGTLQQLFYSITVGQV,” synthesized 
and conjugated to KLH by AnaSpec). In addition, irradiated splenocytes 
from C57BL/6 mice were used as APCs in the hybridoma experiments. All 
experiments were approved by the Stockholm North Committee for Exper-
imental Animal Ethics.
T cell hybridomas. T cell hybridomas were generated by polyethylene 
glycol-induced fusion of 5 × 107 LNs with 3 × 107 BW5147 thymoma cells, 
as previously described (Kappler et al., 1981). In brief, LN cells from the im-
munized mice were stimulated with 3 µg/ml oxLDL for 3 d before fusion. 
After fusion, 106 thymocytes were added as feeder cells, and the cell suspen-
sions were plated in 96-well plates and incubated at 37°C and 7.5% CO2. 
Hypoxanthine-aminopterin-thymidine (HAT) was added to the medium 
after 24 h to select successfully fused cells. HAT-resistant hybridomas were 
then cloned by limiting dilution and screened for their reactivity against na-
tive LDL, copper oxLDL, and ApoB100.
Screen for positive clones. T cell reactivity was measured in 96-well plate   
assays with 105 T hybridoma cells, 4 × 105 irradiated (1.6 Gy) APCs, and LDL 
preparations. APCs were prepared by grinding spleens over nylon filters 
(100 µm), lysing red blood cells, and washing. Concavalin A was used as a 
positive control. Cells were cultured for 24 h at 37°C and 7.5% CO2 in DME 
supplemented with 5% FCS. IL-2 was measured by ELISA (R&D Systems) 
in the culture supernatants to determine T cell activation. To measure the 
extent of cell death in experiments with cultured cells, two independent 
methods were used. First, lactate dehydrogenase (LDH) cytotoxicity assay kit 
(Cayman Chemical Company) was used to measure the amount of LDH in 
culture medium, which indicates degree of apoptosis and necrosis. Second, 
the LiveDead fixable aqua stain kit (Invitrogen) was used to detect cell viabil-
ity of T cell hybridomas according to the manufacturer’s instructions.
TCR genotyping by PCR. Total RNA was prepared from 107 hybridoma 
cells with the RNeasy Mini kit (QIAGEN) and reverse-transcribed into JEM VOL. 207, May 10, 2010 
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fixed cryosections followed by detection with the ABC alkaline phosphatase 
kit (Vector Laboratories). En face lipid accumulation was determined in the 
aortic arch from immunized mice using Sudan IV staining. In brief, dissected 
arches were fixed in 4% neutral buffered formalin. Samples were then cut 
longitudinally, splayed, pinned, and subjected to Sudan IV staining (red 
color). Images were captured using a DC480 camera connected to a MZ6 
stereo microscope (both from Leica). The additive area of all the plaques in 
a given aortic arch was calculated as a percent of the total surface area of the 
arch (not including branching vessels). Quantitation of plaques was per-
formed using ImageJ software (NIH). Immunohistochemical data were ob-
tained using Qwin computerized analysis (Leica) of stained sections.
RNA isolation, cDNA synthesis, and real-time PCR. RNA was iso-
lated from the indicated tissues or cells using the RNeasy kit (QIAGEN).
Total RNA was analyzed on a BioAnalyzer (Agilent Technologies). Reverse 
transcription was performed with Superscript-II and random hexamers (both 
from Invitrogen) and amplified by real time-PCR using Assay-on-demand 
primers and probes for Ccl2, Ccl5, CD3, and hypoxanthine guanidine ribo-
nucleosyl transferase (HPRT) (Applied Biosystems) in an ABI 7700 Se-
quence Detector (Applied Biosystems). For the TRBV31 expression analysis, 
the primers used in the genotyping (Table S2) were combined with a probe 
designed based on the nucleotide sequences of the constant region of TCR 
 chain (5-TCCACCCAAGGTCT-3). The probe was designed using 
ABI Primer Express software (Applied Biosystems) and it was synthesized 
with a 6-carboxy-fluorescein (FAM) reporter molecule attached at the 5 end 
(Applied Biosystems). Data were analyzed on the basis of the relative expres-
sion method with the formula 2CT, where CT = CT (sample) – CT 
(calibrator = mean CT values of all samples within each group), and CT is 
the CT of the housekeeping gene (HPRT) subtracted from the CT of the 
target gene. For TRBV31, values of the mean ± SEM of TRBV31 expres-
sion/CD3 expression are shown.
Antibody-mediated blocking of TRBV31+ cell responses to LDL in 
vitro. Total IgG plasma antibodies from KLH- or TRBV31-immunized 
mice  were  affinity-purified  using  a  protein  G  column  (GE  Healthcare). 
10,000 hybridoma cells (clone 48–5) were cultured with 20 µg/ml LDL in 
the presence of 4 × 104 irradiated APCs. To block hybridoma activation, 
various antibodies were added at the beginning of culture at the concentra-
tions indicated in the figure and were present throughout the culture. After 
24 h of incubation, IL-2 was measured in the supernatant.
Statistical analysis. Values are expressed as mean ± SEM unless otherwise 
indicated. The nonparametric Mann-Whitney U test was used for pairwise 
comparisons and the Kruskal-Wallis test for multiple comparisons. Correla-
tions were calculated using the Spearman test. Differences between groups 
were considered significant at P values below 0.05.
Online supplemental material. Fig. S1 shows negative controls for hy-
bridomal responses and MHC restriction assay. Fig. S2 shows the PCR-
amplified  fragments  from  the  T  cell  receptor  genotyping,  visualized  on 
agarose  gels  and  staining  of  T  cell  receptors  from  ApoB100-responding 
hybridomas. Fig. S3 shows that the antigen preparations used in experi-
ments were not toxic to the cells. Fig. S4 shows that immunization is neces-
sary for priming of T cells and detection of proliferation in vitro. Fig. S5 
shows that immunization with TRBV31 peptide or KLH do not influence 
ApoB100 or lipid levels in plasma. Fig. S6 shows the biochemical evalua-
tion of soluble ApoB100 preparations. Table S1 provides information about   
the T cell receptor genotype from each of the screened hybridomas. Table S2   
lists the primers that were used to genotype the hybridoma T cell receptors.   
Online supplemental material is available at http://www.jem.org/cgi/content/ 
full/jem.20092243/DC1.
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In vitro proliferation assay. Splenocytes from immunized mice were iso-
lated and resuspended. In 96-well plates, 5 × 105 splenocytes were incubated 
in duplicate with different antigens, as described in the figure legends, in 200 
µl of serum-free medium, 1:100 BD ITS+ Premix (BD), 1 mg/ml BSA 
(Sigma-Aldrich), 10 mmol/liter Hepes (Invitrogen), 1 mmol/l Na pyru-
vate (Invitrogen), 1 mmol/l nonessential amino acids (Sigma-Aldrich), and 
50 µg/ml gentamycin sulfate (Sigma-Aldrich) for 72 h, at 37°C in a humid 
5% CO2 atmosphere. One microcurie [3H]thymidine (Sigma-Aldrich) was 
added after 60 h and DNA replication was measured with a scintillation 
counter (Wallac). Results are expressed as stimulation index = (s – c)/c, 
where s is the cpm of the sample with antigen and c is the cpm of the sample 
without antigen.
V+ T cell depletion by fluorescence activated cell sorting. Spleno-
cytes were isolated from huApoB100tg Ldlr/ mice that were immunized 
with  100  ug  ApoB100.  30  million  splenocytes  were  stained  with  anti-
TRBV31 or anti-TRBV19 (BD). TRBV19 was used as a control for the 
sort, because none of the hybridomas that recognized ApoB100 expressed 
this TCR. Two clones that expressed the TRBV19/TRAV13.2 TCR (96.7 
and 97.3) did not recognize LDL or ApoB100 (Table S1). After staining, the 
cells were sorted on a MoFlo Cytomation cell sorter (Cytomation Bioinstru-
ments) to deplete positive events. Negative cells were collected and used in 
the proliferation assay in response to ApoB100.
Plasma analyses. The titers of specific antibodies to TRBV31 peptide, 
LDL, oxLDL and ApoB100 were measured by ELISA. In brief, 50 µl of the 
different antigens (10 µg/ml in PBS pH 7.4) was added to 96-well ELISA 
plates and incubated overnight at 4°C. Coated plates were washed with PBS 
and blocked with 1% gelatin (Invitrogen) in PBS for 1 h at room tempera-
ture. Next, plates were washed and incubated for two additional hours with 
mouse plasma, diluted in TBS/gelatin 0.1%. After washing, total IgG levels 
were measured using enzyme-conjugated anti-mouse antibodies (BD). The 
plates were washed, and colorimetric reactions were developed using TMB 
(BD). The absorbance was measured using a microplate reader (VersaMax; 
MDS Analytical Devices). Plasma cholesterol and triglycerides were mea-
sured using enzymatic colorimetric kits (Randox Laboratory, Ltd.) according 
to the manufacturer’s protocol. ApoB100 levels were measured by commer-
cial ELISA following the manufacturer’s instructions (ALerCHEK, Inc.).
Lipoprotein lipid profiles. Plasma cholesterol lipoprotein profiles were 
determined using a modification of the method of Okazaki et al. (1981). 
In brief, plasma samples (50 µl) from mice immunized with TRBV31-peptide 
or  KLH  were  fractionated  using  an  HR10/30  Superose  6  column  (GE 
Healthcare) and a Discovery BIO GFC-500 as precolumn (5 cm × 7.8 i.d.; 
Supelco; Sigma-Aldrich) coupled to Prominence UFLC system (Shimadzu) 
and equilibrated with Tris-buffered saline, pH 7.4. Fractions of 200 ul were 
collected using Foxy Jr. fraction collector (Teledyne Isco, Inc.) and total 
cholesterol was determined in each fraction using enzymatic colorimetric kit 
(Randox Laboratory, Ltd.).
Tissue processing, immunohistochemistry, and lesion analysis. 
Blood from sacrificed mice was collected by cardiac puncture and vascular 
perfusion performed with sterile RNase-free PBS. Abdominal aorta, one-
third of the spleen, and draining LNs were dissected and snap-frozen for later 
RNA isolation. Hearts and aortic arch were dissected and preserved for 
immunohistochemistry and lesion analysis. Lesion analysis was performed as 
described (Nicoletti et al., 1998). In brief, hearts were serially sectioned from 
the proximal 1 mm of the aortic root on a cryostat. Hematoxylin- and Oil 
red O–stained sections were used to evaluate lesion size. Lesion size was de-
termined by measuring 8 hematoxylin- and Oil Red O–stained sections, 
collected at every 100 µm over a 1 mm segment of the aortic root. For each 
section, images were captured with a DM-LB2 microscope (Leica) equipped 
with a 20×/0.9 objective and a DC300 camera (Leica), and the surface areas 
of the lesion(s) and of the entire vessel were measured. Primary antibodies to 
CD3, CD68, and I-Ab (all rat anti-mouse from BD) were applied to acetone-1092 T cell response to native LDL | Hermansson et al.
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